Skip to main content

Peer Review reports

From: Pan-cancer analysis of the prognostic and immunological role of SNX29: a potential target for survival and immunotherapy

Original Submission
25 Jul 2022 Submitted Original manuscript
30 Jul 2022 Reviewed Reviewer Report - Zihang Zeng
19 Aug 2022 Reviewed Reviewer Report - Jiaheng Xie
19 Sep 2022 Author responded Author comments - Jiangwei Xiao
Resubmission - Version 2
19 Sep 2022 Submitted Manuscript version 2
7 Oct 2022 Author responded Author comments - Jiangwei Xiao
Resubmission - Version 3
7 Oct 2022 Submitted Manuscript version 3
7 Oct 2022 Author responded Author comments - Jiangwei Xiao
Resubmission - Version 4
7 Oct 2022 Submitted Manuscript version 4
8 Oct 2022 Author responded Author comments - Jiangwei Xiao
Resubmission - Version 5
8 Oct 2022 Submitted Manuscript version 5
8 Oct 2022 Author responded Author comments - Jiangwei Xiao
Resubmission - Version 6
8 Oct 2022 Submitted Manuscript version 6
1 Feb 2023 Reviewed Reviewer Report - Zihang Zeng
7 Feb 2023 Reviewed Reviewer Report - Jiaheng Xie
9 Feb 2023 Author responded Author comments - Jiangwei Xiao
Resubmission - Version 7
9 Feb 2023 Submitted Manuscript version 7
12 Feb 2023 Author responded Author comments - Jiangwei Xiao
Resubmission - Version 8
12 Feb 2023 Submitted Manuscript version 8
Publishing
21 Feb 2023 Editorially accepted
24 Feb 2023 Article published 10.1186/s12920-023-01466-2

You can find further information about peer review here.

Back to article page